Life Biosciences Secures First FDA Approval for Human Epigenetic Reprogramming Trial to Reverse Vision Loss
核心洞察
Life Biosciences (搜索), cofounded by Harvard (搜索) geneticist David Sinclair, received FDA approval for the first human trial testing partial epigenetic reprogramming to restore vision in patients with glaucoma (搜索) and NAION (搜索).
The Phase 1 trial will inject viruses carrying three reprogramming genes directly into patients' eyes, with the treatment controlled by doxycycline antibiotic dosing over two months.
This breakthrough puts the Boston startup ahead of well-funded competitors like Altos Labs (搜索) and NewLimit (搜索) in the race to develop age reversal therapies.
Life Biosciences (搜索), a Boston biotech company cofounded by Harvard (搜索) genetics professor David Sinclair, announced Wednesday it has secured FDA approval for a groundbreaking Phase 1 clinical trial aimed at restoring vision through "partial epigenetic reprogramming." The trial represents the first FDA-approved human study attempting to reverse cellular aging, positioning the lean startup ahead of heavily funded competitors in the emerging longevity field.
Revolutionary Approach to Vision Restoration
The trial will target patients with glaucoma (搜索) and non-arteritic anterior ischemic optic neuropathy (搜索) (NAION (搜索)), two conditions that can cause blindness through optic nerve (搜索) damage. Researchers plan to inject viruses carrying three powerful reprogramming genes directly into patients' eyes to deliver "rejuvenation instructions" to damaged retinal ganglion cells (搜索).
"It's a transformational day, I think, for science overall, for Life Biosciences (搜索), for the field of partial epigenetic reprogramming," said CEO Jerry McLaughlin, a pharmaceutical industry veteran who previously worked at Merck (搜索) and venture-backed biotechs including Neos Therapeutics and AgeneBio (搜索).
The company will enroll its first patients over the next couple of months, with results potentially coming by the end of the year or early next year, according to McLaughlin.
Targeting High-Impact Eye Diseases
Life Biosciences (搜索) chose to focus on optic neuropathies due to their significant patient impact. Glaucoma (搜索) is the second leading cause of blindness worldwide according to the Centers for Disease Control and Prevention, particularly affecting adults between ages 64 and 84. NAION (搜索) is the "most common acute, optic neuropathy" in people over 50.
"The bad news is there's absolutely nothing to treat [NAION (搜索)], and the even worse news is that there's about a 20-to-30% chance in the next two to three years it's going to happen in the second eye," McLaughlin explained.
Scientific Foundation and Safety Measures
The treatment is based on Nobel Prize-winning research by Japanese scientist Shinya Yamanaka, who discovered that four specific proteins could reset stem cells to a pluripotent state. Sinclair's innovation involved using only three of these "Yamanaka factors (搜索)" to partially rejuvenate cells without causing them to "forget" their original function—a critical safety consideration since fully reset cells can turn into tumors.
The trial will test approximately a dozen patients with glaucoma (搜索) initially. To ensure safety, the reprogramming genes will be controlled by a genetic switch that activates only when patients take low doses of the antibiotic doxycycline for about two months while effects are monitored.
Sinclair's foundational research, published in Nature in 2020 under the headline "Turning Back Time," demonstrated that partial reprogramming could restore vision to mice after optic nerve (搜索) damage. Life Biosciences (搜索) then licensed the technology from Harvard (搜索) and tested it in non-human primates, where McLaughlin said the company successfully induced NAION (搜索)-like injury and then reversed vision loss to restore it to healthy primate levels.
Competitive Landscape and Industry Impact
The FDA approval puts Life Biosciences (搜索)' team of fewer than 20 people ahead of well-funded competitors in the longevity space. Altos Labs (搜索) launched with $3 billion in funding in 2022 and reportedly counts Amazon founder Jeff Bezos as an early backer. NewLimit (搜索), cofounded by Coinbase CEO Brian Armstrong, raised $130 million in Series B financing to pursue epigenetic reprogramming.
"Reprogramming is like the AI of the bio world. It's the thing everyone is funding," said Karl Pfleger, an investor backing UK startup Shift Bioscience (搜索).
Other companies studying reprogramming acknowledge Life Biosciences (搜索)' lead position. "I think they're way ahead of anybody else in terms of getting into humans. They have found a route forward in the eye, which is a nice self-contained system. If it goes wrong, you've still got one left," said Daniel Ives, CEO of Shift Bioscience (搜索).
Broader Implications and Future Applications
While the current trial focuses on vision restoration, McLaughlin said Life Biosciences (搜索) has already applied its epigenetic reprogramming approach to other conditions, including liver fibrosis (搜索) (MASH (搜索)), demonstrating that the approach "transcends organs." The company has discussed the possibility of reprogramming other organs, including the brain.
The work addresses broader demographic challenges, as McLaughlin noted: "Our population replacement is not there in the U.S. We're well below population replacement. It's worse in other parts of the world, and with a rapidly aging population, extending healthy human lifespan is critical, from an economic standpoint, and for society overall."
The U.S. fertility rate hit a record low of 1.6 children per woman in 2024, below the replacement level of 2.1 children per woman, according to World Bank data.
Technical Challenges and Future Development
Despite the breakthrough, significant technical challenges remain. The antibiotic switching mechanism, while commonly used in laboratory animals, hasn't been tested in humans before. Since the switch uses gene components from E. coli and herpes virus, it could potentially cause immune reactions in humans.
The choice of three reprogramming factors (known by the acronym OSK) may also carry risks, as they're expected to activate hundreds of other genes and could potentially cause cells to revert to primitive stem-cell states under certain circumstances.
"Are their factors the best version of rejuvenation? We don't think they are. I think they are working with what they've got," Ives said, while acknowledging Life Biosciences (搜索)' pioneering position in human trials.
The trial represents a proof of concept that remains far from a universal fountain of youth. "The optimistic case is this solves some blindness for certain people and catalyzes work in other indications," Pfleger noted. "It's not like your doctor will be writing a prescription for a pill that will rejuvenate you."